ArticleERJ open research2023
Early selexipag initiation and long-term outcomes: insights from randomised controlled trials in pulmonary arterial hypertension.
Article in ERJ open research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 17 citations in OpenAlex.
- Reply to the Letter to the Editor: "Risk Trajectory and Right Ventricular Adaptation in Selexipag- Based Triple Therapy for Pulmonary Arterial Hypertension".Anatolian journal of cardiology · 2026Article
- Real-World Experience with Selexipag in Patients with Pulmonary Arterial Hypertension: Treatment Patterns and Outcomes across Baseline Risk Strata (SPHERE and EXPOSURE Studies).Drugs - real world outcomes · 2026Article
- Could We Maintain the Initial Efficacy of Triple Sequential Combination Therapies with Selexipag Against Progressive Deterioration Risk in Patients with Pulmonary Arterial Hypertension: Insights from a Single-Center Study?Anatolian journal of cardiology · 2026Article
- Improved cardiac function and quality of life with initial macitentan-tadalafil combination therapy compared to tadalafil alone in pulmonary arterial hypertension.American journal of translational research · 2026Article
- Upfront triple combination therapy with selexipag: insights from a real world cohort in Chinese patients with pulmonary arterial hypertension.Frontiers in cardiovascular medicine · 2026Article
- Congruency between clinician-assessed risk and calculated risk of 1-year mortality in patients with pulmonary arterial hypertension: A retrospective chart review.Pulmonary circulation · 2024Article
- Treatment algorithm for pulmonary arterial hypertension.The European respiratory journal · 2024Review
- Early Addition of Selexipag to Double Therapy for Pulmonary Arterial Hypertension.JAMA network open · 2024Article
- Four-Strata Risk Assessment in Patients with Pulmonary Arterial Hypertension Treated with Selexipag in Real-World Settings (EXPOSURE Study).Advances in therapy · 2024Article
- Selexipag in patients with pulmonary arterial hypertension associated with connective tissue disease (PAH-CTD): Real-world experience from EXPOSURE.Pulmonary circulation · 2024Article
- Impact of different sequential triple oral combination therapies based selexipag on outcomes in pulmonary arterial hypertension.Clinical cardiology · 2024Article
- Evaluating the efficacy and safety of oral triple sequential combination therapy for treating patients with pulmonary arterial hypertension: A multicenter retrospective study.Pulmonary circulation · 2024Article
- Review
- When more is more: the role of additional upfront therapy in pulmonary arterial hypertension.ERJ open research · 2023Article
- Long-term impact of add-on sequential triple combination therapy in pulmonary arterial hypertension: real world experience.Therapeutic advances in respiratory diseaseObservational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 13 institutions in 8 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Further understanding of when to initiate therapies in pulmonary arterial hypertension (PAH) is important to improve long-term outcomes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.